ArticleFrontiers in immunology2026
ZIC2 drives colorectal cancer progression by regulating QPRT-mediated cell migration.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commentary: ZIC2 drives colorectal cancer progression by regulating QPRT-mediated cell migration.Frontiers in immunology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is characterized by high mortality. Zinc finger protein ZIC2 plays a dual role in various cancers; however, its clinical value of ZIC2 in CRC remains unclear. Methods: TCGA cohort data, GEO datasets (GSE39582 and GSE139555), and a CRC_10x spatial transcriptomics dataset were used for molecular feature analysis of ZIC2 to confirm its expression and clinical significance in cancer. These analyses included bulk transcriptomic analysis, single-cell transcriptomic analysis, and spatial transcriptomic analysis. Weighted gene co-expression network analysis (WGCNA) was used to identify the genes interacting with ZIC2. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to explore the potential mechanisms of ZIC2 in CRC. Cytological assays were conducted to validate the expression, function, and mechanism of ZIC2 in CRC. The effect of ZIC2 on cell migration was evaluated using cell scratch assays. Results: ZIC2 was upregulated in most cancer tissues compared with normal tissues, and high ZIC2 expression was associated with poor prognosis. ZIC2 expression of ZIC2 was positively correlated with tumor mutational burden (TMB) and microsatellite instability (MSI). Multiple tumor-related pathways were differentially enriched between high and low ZIC2 expression phenotypes in CRC, particularly the Wnt signaling pathway and stem cell-related pathways. WGCNA identified quinolinate phosphoribosyltransferase (QPRT) as a potential downstream target regulated by ZIC2. Functional validation demonstrated that ZIC2 overexpression significantly enhanced colorectal cancer cell migration and proliferation, accompanied by upregulation of QPRT. Importantly, treatment with phthalic acid, a QPRT inhibitor, partially reversed the ZIC2-induced enhancement of cell migration, indicating that ZIC2 promotes CRC cell migration through a QPRT-dependent mechanism. Conclusion: ZIC2 may serve as a valuable prognostic and prognostic biomarker in pan-cancer, including CRC. ZIC2 may promote the colorectal cancer progression by upregulating QPRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.